ChromaCon
Develops and commercialises proprietary chromatographic process technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ChromaCon specializes in continuous chromatography systems designed for process and pilot scale applications, offering seamless scale-up from lab to production. The company focuses on high-yield purification of peptides, oligonucleotides, and natural products, serving clients in the biopharmaceutical and bioprocessing industries. Operating in the global chromatography market, ChromaCon's business model revolves around providing advanced purification systems that maximize yield and purity. Revenue is generated through the sale of GMP-grade systems capable of batch, integrated batch, and CaptureSMB processes. The company's offerings include the Contichrom CUBE and the YMC EcoPrime TWIN systems, which are designed to enhance productivity and efficiency in biotherapeutic purification. ChromaCon's technology is utilized by organizations seeking to optimize their purification processes, including the FDA, which has adopted their continuous technology. The company continues to collaborate with YMC for the development of GMP pilot and production scale systems.
Keywords: chromatography, purification, peptides, oligonucleotides, biopharmaceutical, bioprocessing, GMP-grade, CaptureSMB, Contichrom, YMC